New Long-Acting shot tested for opioid addiction

NCT ID NCT06576843

Completed Disease control Sponsor: Indivior Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested a new long-acting injectable medication called INDV-6001 for adults with moderate to severe opioid addiction. The goal was to see how the drug behaves in the body, how safe it is, and to find the best dose for future studies. Researchers compared it to existing treatments and tested different injection sites like the arm and thigh.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Artemis Institute for Clinical Research

San Diego, California, 92103, United States
Chicago Clinical Research Institute Inc.

Chicago, Illinois, 60607, United States
Hassman Research Institute (Cenexel HRI - Marlton)

Marlton, New Jersey, 08053, United States
Innovative Clinical Research, Inc.

Miami Lakes, Florida, 33016, United States
Insite Clinical Research, LLC

DeSoto, Texas, 75115, United States
Memorial Hermann Village

Houston, Texas, 77043, United States
Midwest Clinical Research

Dayton, Ohio, 45417, United States
Pillar Clinical Research

Richardson, Texas, 75080, United States
Precise Research Centers

Flowood, Mississippi, 39232, United States
Progressive Clinical Research

Bountiful, Utah, 84010, United States
Richmond Behavioral Associates

Staten Island, New York, 10314, United States

Conditions

Explore the condition pages connected to this study.

MODERATE TO SEVERE OPIOID USE DISORDER